Core Viewpoint - The company, 博瑞医药, plans to increase its investment in 苏州极客基因科技有限公司 by 50 million RMB, raising its ownership stake from 4.0816% to 12.8015% [1] Group 1: Investment Details - The investment will consist of a subscription for an additional registered capital of 437,100 RMB, with the remaining amount added to the company's capital reserve [1] - The pre-investment valuation of 极客基因 was determined to be 500 million RMB [2] Group 2: Company Profile - 极客基因 specializes in innovative cell drug development, focusing on single-cell sequencing services and immune cell therapy [1] - The company has developed a world-leading single-cell multi-omics data collection platform and a low-cost high-throughput omics technology platform [1] - 极客基因 is currently developing long-lived tumor-reactive T-cell drugs for the treatment of advanced solid tumors [1]